97 related articles for article (PubMed ID: 27064084)
1. Imaging and histologic prognostic factors in triple-negative breast cancer and carcinoma in situ as a prognostic factor.
Sebastián Sebastián C; García Mur C; Cruz Ciria S; Rosero Cuesta DS; Gros Bañeres B
Radiologia; 2016; 58(4):283-93. PubMed ID: 27064084
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the radio-pathological factors of triple negative breast cancer and determination of risk profiles.
Sebastián Sebastián C; García Mur C; Gros Bañeres B; Cruz Ciria S; Rosero Cuesta DS; Suñén Amador I
Radiologia (Engl Ed); 2020; 62(5):365-375. PubMed ID: 32093905
[TBL] [Abstract][Full Text] [Related]
3. Triple-negative breast carcinoma: heterogeneity in immunophenotypes and pharmacokinetic behavior.
Vilagran Fraguell M; Sentís Crivillé M; del Riego Ferrari J; Andreu Navarro FJ; Dalmau Portulàs E; Planas Roquerols J; Lluïsa Baré M
Radiologia; 2016; 58(1):55-63. PubMed ID: 26433625
[TBL] [Abstract][Full Text] [Related]
4. Perfusion Parameters on Breast Dynamic Contrast-Enhanced MRI Are Associated With Disease-Specific Survival in Patients With Triple-Negative Breast Cancer.
Park VY; Kim EK; Kim MJ; Yoon JH; Moon HJ
AJR Am J Roentgenol; 2017 Mar; 208(3):687-694. PubMed ID: 28004976
[TBL] [Abstract][Full Text] [Related]
5. Breast parenchymal signal enhancement ratio at preoperative magnetic resonance imaging: association with early recurrence in triple-negative breast cancer patients.
Park VY; Kim EK; Kim MJ; Yoon JH; Moon HJ
Acta Radiol; 2016 Jul; 57(7):802-8. PubMed ID: 26516288
[TBL] [Abstract][Full Text] [Related]
6. Association between rim enhancement of breast cancer on dynamic contrast-enhanced MRI and patient outcome: impact of subtype.
Schmitz AM; Loo CE; Wesseling J; Pijnappel RM; Gilhuijs KG
Breast Cancer Res Treat; 2014 Dec; 148(3):541-51. PubMed ID: 25376743
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment MR Imaging Features of Triple-Negative Breast Cancer: Association with Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival.
Bae MS; Shin SU; Ryu HS; Han W; Im SA; Park IA; Noh DY; Moon WK
Radiology; 2016 Nov; 281(2):392-400. PubMed ID: 27195438
[TBL] [Abstract][Full Text] [Related]
8. Triple-negative breast cancer: Pretreatment magnetic resonance imaging features and clinicopathological factors associated with recurrence.
Lee YJ; Youn IK; Kim SH; Kang BJ; Park WC; Lee A
Magn Reson Imaging; 2020 Feb; 66():36-41. PubMed ID: 31785544
[TBL] [Abstract][Full Text] [Related]
9. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
Ma F; Ding X; Fan Y; Ying J; Zheng S; Lu N; Xu B
PLoS One; 2014; 9(11):e112765. PubMed ID: 25393310
[TBL] [Abstract][Full Text] [Related]
10. Morphological and Semiquantitative Kinetic Analysis on Dynamic Contrast Enhanced MRI in Triple Negative Breast Cancer Patients.
Gigli S; Amabile MI; David E; De Luca A; Grippo C; Manganaro L; Monti M; Ballesio L
Acad Radiol; 2019 May; 26(5):620-625. PubMed ID: 30145205
[TBL] [Abstract][Full Text] [Related]
11. Early Stage Triple-Negative Breast Cancer: Imaging and Clinical-Pathologic Factors Associated with Recurrence.
Bae MS; Moon HG; Han W; Noh DY; Ryu HS; Park IA; Chang JM; Cho N; Moon WK
Radiology; 2016 Feb; 278(2):356-64. PubMed ID: 26230976
[TBL] [Abstract][Full Text] [Related]
12. Associations Between Magnetic Resonance Imaging Findings and Clincopathologic Factors in Triple-Negative Breast Cancer.
Choi BB; Kim SH; Youn I
J Comput Assist Tomogr; 2019; 43(2):252-256. PubMed ID: 30664119
[TBL] [Abstract][Full Text] [Related]
13. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
[TBL] [Abstract][Full Text] [Related]
14. Is there different correlation with prognostic factors between "non-mass" and "mass" type invasive ductal breast cancers?
Jiang L; Zhou Y; Wang Z; Lu X; Chen M; Zhou C
Eur J Radiol; 2013 Sep; 82(9):1404-9. PubMed ID: 23540946
[TBL] [Abstract][Full Text] [Related]
15. Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.
Dong T; Kang X; Liu Z; Zhao S; Ma W; Xuan Q; Liu H; Wang Z; Zhang Q
Tumour Biol; 2016 Jun; 37(6):8159-68. PubMed ID: 26715276
[TBL] [Abstract][Full Text] [Related]
16. Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-negative Breast Cancer-A Single Centre Prospective Observational Study.
Constantinou C; Papadopoulos S; Karyda E; Alexopoulos A; Agnanti N; Batistatou A; Harisis H
In Vivo; 2018; 32(2):303-311. PubMed ID: 29475913
[TBL] [Abstract][Full Text] [Related]
17. Comparison of invasive micropapillary and triple negative invasive ductal carcinoma of the breast.
Chen HL; Ding A
Breast; 2015 Dec; 24(6):723-31. PubMed ID: 26392199
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathological features and prognosis of triple-negative breast cancer].
Li CY; Wang P; Zhang S; Liu Y; Zhang J
Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):463-7. PubMed ID: 24119909
[TBL] [Abstract][Full Text] [Related]
19. MR imaging features of triple-negative breast cancers.
Sung JS; Jochelson MS; Brennan S; Joo S; Wen YH; Moskowitz C; Zheng J; Dershaw DD; Morris EA
Breast J; 2013; 19(6):643-9. PubMed ID: 24015869
[TBL] [Abstract][Full Text] [Related]
20. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
